A5063615518- Viral Infections and Outbreaks Research
- Viral Infections and Vectors
- Hepatitis B Virus Studies
- Cell Adhesion Molecules Research
- Vaccine Coverage and Hesitancy
- Glycosylation and Glycoproteins Research
- COVID-19 epidemiological studies
- Disaster Response and Management
- Platelet Disorders and Treatments
- Global Security and Public Health
- SARS-CoV-2 and COVID-19 Research
- Mosquito-borne diseases and control
- Virus-based gene therapy research
- Immune Cell Function and Interaction
- Respiratory viral infections research
- Malaria Research and Control
- Genetics, Aging, and Longevity in Model Organisms
- Immunodeficiency and Autoimmune Disorders
- Virology and Viral Diseases
- HIV Research and Treatment
- Blood disorders and treatments
- Galectins and Cancer Biology
- Invertebrate Immune Response Mechanisms
- Biofuel production and bioconversion
- Reproductive tract infections research
Janssen (Netherlands)
2016-2025
Janssen (Switzerland)
2021
Janssen (United States)
2016
MRC Human Immunology Unit
2006-2012
John Radcliffe Hospital
2007-2012
University of Oxford
2006-2012
MRC Weatherall Institute of Molecular Medicine
2011
Medizinische Hochschule Hannover
2008
Royal Hospital for Sick Children
2006
University of Münster
2000-2006
<h3>Importance</h3> Developing effective vaccines against Ebola virus is a global priority. <h3>Objective</h3> To evaluate an adenovirus type 26 vector vaccine encoding glycoprotein (Ad26.ZEBOV) and modified vaccinia Ankara vaccine, glycoproteins from virus, Sudan Marburg Tai Forest nucleoprotein (MVA-BN-Filo). <h3>Design, Setting, Participants</h3> Single-center, randomized, placebo-controlled, observer-blind, phase 1 trial performed in Oxford, United Kingdom, enrolling healthy 18- to...
Ebola vaccine development was accelerated in response to the 2014 virus infection outbreak. This phase 1 study (VAC52150EBL1004) assessed safety, tolerability, and immunogenicity of heterologous 2-dose Ad26.ZEBOV, MVA-BN-Filo vaccination regimens Lake Victoria Basin Tanzania Uganda mid-level altitude, malaria-endemic settings.
During the 2014 West African Ebola outbreak, vaccine development was accelerated. The phase 1 VAC52150EBL1003 study performed to investigate 2-dose heterologous vaccination with Ad26.ZEBOV and MVA-BN-Filo in an population located a high-altitude setting Nairobi, Kenya. Healthy adult volunteers were randomized receive one of four schedules. first administered at baseline (Ad26.ZEBOV or MVA-BN-Filo), followed by second alternate after either 28 56 days. Each schedule had placebo comparator...
Reoccurring Ebola outbreaks in West and Central Africa have led to serious illness death thousands of adults children. The objective this study was assess safety, tolerability, immunogenicity the heterologous 2-dose Ad26.ZEBOV, MVA-BN-Filo vaccination regimen adolescents children Africa.In multicentre, randomised, observer-blind, placebo-controlled Phase II study, 131 (12 17 years old) 132 (4 11 were enrolled from Eastern Western randomised 5:1 receive vaccines or placebo. Vaccine groups...
The emergence of Marburg virus (MARV) in Guinea and Ghana triggered the assembly MARV vaccine “MARVAC” consortium representing leaders field research development aiming to facilitate a rapid response this infectious disease threat. Here, we discuss current progress, challenges, future directions for vaccines.
Dengue virus infection is an increasingly important tropical disease, causing 100 million cases each year. Symptoms range from mild febrile illness to severe hemorrhagic fever. The pathogenesis incompletely understood, but immunopathology thought play a part, with antibody-dependent enhancement and massive immune activation of T cells monocytes/macrophages leading disproportionate production proinflammatory cytokines. We sought investigate whether defective population regulatory (T reg...
Vaccinia Virus Ankara-Vectored Ebola Vaccines at 1 YearThe virus vaccine strategies evaluated by the World Health Organization in response to 2014-2016 outbreak West Africa included a heterologous primary and booster vaccination schedule of adenovirus type 26 vector encoding glycoprotein (Ad26.ZEBOV) modified vaccinia Ankara vaccine, glycoproteins from Ebola, Sudan, Marburg, Tai Forest viruses nucleoprotein (MVA-BN-Filo).This has been shown induce immune responses that persist for 8 months...
Abstract It has been proven challenging to conduct traditional efficacy trials for Ebola virus (EBOV) vaccines. In the absence of data, immunobridging is an approach infer likelihood a vaccine protective effect, by translating immunogenicity in humans using relationship between and desired outcome suitable animal model. We here propose effect Ad26.ZEBOV, MVA-BN-Filo regimen with 8-week interval immunobridging. Immunogenicity data were obtained Ad26.ZEBOV regimens fully lethal EBOV Kikwit...
The consequences of the 2013–16 Ebola Zaire virus disease epidemic in West Africa were grave. economies, healthcare systems and communities Guinea, Sierra Leone Liberia devastated by over 18 months active transmission, followed sporadic resurgences potentially related to sexual transmission survivors with viral persistence body fluids following recovery. need develop implement strategies prevent mitigate future outbreaks is now beyond dispute. potential for unpredictable indeterminate...
We investigated safety, tolerability, and immunogenicity of the heterologous 2-dose Ebola vaccination regimen in healthy HIV-infected adults with different intervals between vaccinations.
Leukocyte adhesion deficiency II has been described in only 2 patients; herein we report extensive investigation of another patient. The physical stigmata were detected during prenatal ultrasonographic investigation. Sialyl-Lewis X (sLex) was absent from the surface polymorphonuclear neutrophils, and cell binding to E- P-selectin severely impaired, causing an immunodeficiency. elevation peripheral neutrophil counts occurred within several days after birth. A severe hypofucosylation...
BackgroundDengue is one of the most important human diseases transmitted by an arthropod vector and incidence dengue virus infection has been increasing – over half world's population now live in areas at risk infection. Most infections are asymptomatic, but a subset patients experience potentially fatal shock syndrome characterised plasma leakage. Severe forms epidemiologically associated with repeated more than four serotypes. Generally attributed to phenomenon antibody-dependent...
Invariant NKT (iNKT) cells have an indubitable role in antiviral immunity, although the mechanisms by which these exert their functions are not fully elucidated. With emerging importance of high-pathogenicity influenza A virus infections humans, we questioned whether iNKT contribute to immune defence against and activation influences outcome. We show that with alpha-galactosylceramide (alpha-GC) during infection transiently enhanced early innate response without affecting T cell reduced...
Ebola virus disease (EVD) continues to be a significant public health problem in sub-Saharan Africa, especially the Democratic Republic of Congo (DRC). Large-scale vaccination during outbreaks may reduce transmission. We established large population-based clinical trial heterologous, two-dose prophylactic vaccine an outbreak eastern DRC determine effectiveness.This open-label, non-randomised, enrolled eligible adults and children aged 1 year above. Participants were offered candidate EVD...
Background Though clinically similar, Ebola virus disease and Marburg are caused by different viruses. Of the 30 documented outbreaks of these diseases in sub-Saharan Africa, eight were major (≥200 cases; five Zaire ebolavirus [EBOV], two Sudan [SUDV], one [MARV]). Our purpose is to develop a multivalent vaccine regimen protecting against each filoviruses. This first-in-human study assessed safety immunogenicity several two-dose regimens that contain Ad26.Filo MVA-BN-Filo. Methods combines...
The Janssen Ebola virus (EBOV) vaccine consists of the adenovirus type 26 vector encoding EBOV glycoprotein (GP) (Ad26.ZEBOV) and modified vaccinia Ankara (MVA) GP from EBOV, Sudan virus, Marburg nucleoprotein Tai Forest (MVA-BN-Filo) administered 8 weeks later. We conducted a systems immunology analysis antibody-mediated cellular immune responses induced after two immunizations with either used first. response to vaccination was specific defined by high antibody binding, Fc effector,...
This phase 1 placebo-controlled study assessed the safety and immunogenicity of 2-dose regimens Ad26.ZEBOV (adenovirus serotype 26 [Ad26]) MVA-BN-Filo (modified vaccinia Ankara [MVA]) vaccines with booster vaccination at day 360.Healthy US adults (N = 164) randomized into 10 groups received saline placebo or standard high doses Ad26 MVA in 7-, 14-, 28-, 56-day intervals; 8 vaccinations on 360. Participants reported solicited unsolicited reactogenicity; we measured immunoglobulin G binding,...
The Marburg virus (MARV) and Sudan (SUDV) belong to the filovirus family. sporadic human outbreaks occur mostly in Africa are characterized by an aggressive disease course with high mortality. first case of Guinea 2021, together increased frequency Ebola (EBOV), which is also a filovirus, accelerated interest potential prophylactic vaccine solutions against multiple filoviruses. We previously tested two-dose heterologous regimen (Ad26.Filo, MVA-BN-Filo) non-human primates (NHP) showed fully...